Smith Stan 4

What Happened
Stan Smith, a director of MAIA Biotechnology, purchased 75,000 shares on June 1, 2026. The filing reports a weighted-average purchase price of $1.34 per share, for a total reported outlay of $100,200. The shares were acquired via open-market transactions (purchase code P), which investors often view as a more bullish sign than a sale, though the filing does not state Mr. Smith’s motive.

Key Details

• Transaction date: June 1, 2026; filing date: June 2, 2026 (timely).
• Reported weighted-average price: $1.34 per share; total reported value: $100,200.
• Price range and multiple trades: purchases occurred at prices from $1.32 to $1.40 (F1); reporting person can provide breakdown on request.
• Shares owned after transaction: not disclosed in this filing.
• Beneficial ownership notes: some MAIA shares are held through trusts and UTMA accounts associated with Mr. Smith (F2–F5); he disclaims beneficial ownership of the family-member accounts except to the extent of any pecuniary interest.
• Transaction code: P = Purchase (open-market/private purchase).

Context
This was a direct purchase of common stock (not an option exercise, award, or gift). Purchases by insiders can be of interest to retail investors as a signal of confidence, but filings do not explain the insider’s intent.